- Home
- SKYE vs WHF Comparison
SKYE vs WHF Comparison
Compare SKYE & WHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- WHF
- Stock Information
- Founded
- SKYE 2012
- WHF 2011
- Country
- SKYE United States
- WHF United States
- Employees
- SKYE N/A
- WHF N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- WHF Finance Companies
- Sector
- SKYE Health Care
- WHF Finance
- Exchange
- SKYE Nasdaq
- WHF Nasdaq
- Market Cap
- SKYE 108.3M
- WHF 275.2M
- IPO Year
- SKYE N/A
- WHF 2012
- Fundamental
- Price
- SKYE $4.94
- WHF $11.91
- Analyst Decision
- SKYE Buy
- WHF Hold
- Analyst Count
- SKYE 6
- WHF 3
- Target Price
- SKYE $18.67
- WHF $12.75
- AVG Volume (30 Days)
- SKYE 308.0K
- WHF 55.7K
- Earning Date
- SKYE 11-09-2024
- WHF 11-07-2024
- Dividend Yield
- SKYE N/A
- WHF 12.96%
- EPS Growth
- SKYE N/A
- WHF 62.93
- EPS
- SKYE N/A
- WHF 0.98
- Revenue
- SKYE N/A
- WHF $100,458,000.00
- Revenue This Year
- SKYE N/A
- WHF N/A
- Revenue Next Year
- SKYE N/A
- WHF N/A
- P/E Ratio
- SKYE N/A
- WHF $12.09
- Revenue Growth
- SKYE N/A
- WHF 1.22
- 52 Week Low
- SKYE $1.44
- WHF $10.95
- 52 Week High
- SKYE $19.41
- WHF $13.44
- Technical
- Relative Strength Index (RSI)
- SKYE 58.26
- WHF 55.90
- Support Level
- SKYE $4.01
- WHF $11.77
- Resistance Level
- SKYE $5.48
- WHF $11.98
- Average True Range (ATR)
- SKYE 0.46
- WHF 0.17
- MACD
- SKYE 0.19
- WHF 0.04
- Stochastic Oscillator
- SKYE 73.79
- WHF 80.70
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate attractive risk-adjusted returns for investors, primarily by originating senior secured loans to privately held small-cap companies across a broad range of industries.